Loss of the preconditioning effect of rosuvastatin during sustained therapy: A human in vivo study

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 1, 2012, Pages

  Liuni, Andrew ^a,b   Luca, Mary Clare ^a,b   Gori, Tommaso ^c   Parker, John D ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme a reductase inhibitor; Endothelium; Ischemia; Reperfusion

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CELECOXIB; CHOLESTEROL; CYCLOOXYGENASE 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPEREMIA; IN VIVO STUDY; ISCHEMIA; ISCHEMIC PRECONDITIONING; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; SINGLE DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BLOOD FLOW VELOCITY; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPEREMIA; ISCHEMIA; MALE; ONTARIO; PYRAZOLES; PYRIMIDINES; RADIAL ARTERY; REGIONAL BLOOD FLOW; REPERFUSION INJURY; SULFONAMIDES; TIME FACTORS; VASODILATION; YOUNG ADULT;

EID: 84255167141     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00083.2011     Document Type: Article

References (36)

1. Anonymous. Prevention of cardiovascular events, and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349-1357, 1998.
2. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S.). Lancet 344: 1383-1389, 1994.
3. Atar S, Ye Y, Lin Y, Freeberg S, Nishi S, Rosanio S, Huang M, Uretsky B, Perez-Polo J, Birnbaum Y. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290: H1960-H1968, 2006.
4. Bartoli G, Menegaz G, Lisi M, Di Stolfo G, Dragoni S, Gori T. Model-based analysis of flow-mediated dilation and intima-media thickness. Int J Biomed Imaging 2008: 738545, 2008.
5. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, Uretsky BF. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 65: 345-355, 2005.
6. Corsini A, Ferri N, Cortellaro M. Are pleiotropic effects of statins real? Vasc Health Risk Manag 3: 611-613, 2007.
7. Depre C, Park JY, Shen YT, Zhao X, Qiu H, Yan L, Tian B, Vatner SF, Vatner DE. Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. Am J Physiol Heart Circ Physiol 299: H752-H762, 2010.
8. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 66: 462-471, 2005.
9. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 54: 558-565, 2009.
10. Dragoni S, Gori T, Di Stolfo G, Sicuro S, Forconi S, Parker JD. Folic Acid does not limit endothelial dysfunction induced by ischemia and reperfusion: a human study. J Cardiovasc Pharmacol 46: 494-497, 2005.
11. Dragoni S, Gori T, Lisi M, Di Stolfo G, Pautz A, Kleinert H, Parker JD. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol 27: 1955-1959, 2007.
12. Gori T, Di Stolfo G, Sicuro S, Dragoni S, Lisi M, Forconi S, Parker JD. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol 64: 145-150, 2007.
13. Gori T, Dragoni S, Di Stolfo G, Sicuro S, Liuni A, Luca MC, Thomas GR, Oelze M, Daiber A, Parker JD. "Tolerance" to nitroglycerininduced preconditioning of the endothelium: a human in vivo study. Am J Physiol Heart Circ Physiol 298: H340-H345, 2010.
14. Gori T, Dragoni S, Lisi M, Di Stolfo G, Sonnati S, Fineschi M, Parker JD. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol 51: 1953-1958, 2008.
15. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 111: 742-746, 2005.
16. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 360: 7-22, 2002.
17. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23: 176-182, 2003.
18. Ichihara K, Satoh K, Abiko Y. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J Cardiovasc Pharmacol 22: 852-856, 1993.
19. Kharbanda RK, Peters MJ, Walton B, Kattenhorn M, Mullen MJ, Klein N, Vallance P, Deanfield JE, MacAllister RJ. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 103: 1624- 1630, 2001.
20. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942: 23-30, 2002.
21. Lazar HL, Bao Y, Zhang Y, Bernard SA. Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 125: 1037-1042, 2003.
22. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
23. Liuni A, Luca MC, Gori T, Parker JD. The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury. Clin Hemorheol Microcirc 45: 161-167, 2010.
24. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 55: 1002-1006, 2010.
25. Liuni A, Luca MC, Lisi M, Dragoni S, di Stolfo G, Mariani JA, Uxa A, Gori T, Parker JD. Observations of time-based measures of flowmediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. Am J Physiol Heart Circ Physiol 299: H939-H945, 2010.
26. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection-more than just lipid lowering? Pharmacol Ther 122: 30-43, 2009.
27. Mensah K, Mocanu M, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45: 1287-1291, 2005.
28. Merla R, Daher IN, Ye Y, Uretsky BF, Birnbaum Y. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J 154: 391-402, 2007.
29. Mocanu MM, Yellon DM. PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury? Br J Pharmacol 150: 833-838, 2007.
30. Naito Y, Katada K, Takagi T, Tsuboi H, Kuroda M, Handa O, Kokura S, Yoshida N, Ichikawa H, Yoshikawa T. Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein. World J Gastroenterol 12: 2024-2030, 2006.
31. Rendig SV, Symons JD, Amsterdam EA. Effects of statins on myocardial and coronary artery response to ischemia-reperfusion. Can J Physiol Pharmacol 81: 1064-1071, 2003.
32. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, Koenig W, Libby P, Lorenzatti A, MacFadyen J, Nordestgaard B, Shepherd J, Willerson J, Glynn R. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008.
33. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232-1235, 2005.
34. Shen YT, Depre C, Yan L, Park JY, Tian B, Jain K, Chen L, Zhang Y, Kudej RK, Zhao X, Sadoshima J, Vatner DE, Vatner SF. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation 118: 1961-1969, 2008.
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995.
36. Ye Y, MacAllister RJ, Perez-Polo J, Lin Y, Uretsky B, Birnbaum Y. The role of eNOS, iNOS, and NF-κB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 295: H343-H351, 2008.